Market Size of Cryptococcosis Therapeutics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.70 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Cryptococcosis Therapeutics Market Analysis
Cryptococcosis is a fungal infection which is caused by Cryptococcus neoformans and Cryptococcus gattii which primarily affects the central nervous system and the lungs. People with diseases such as AIDS, hodgkin lymphoma, other lymphomas, sarcoidosis, and solid organ transplantation with weakened immune systems are generally more susceptible to this type of infection.
Cryptococcosis is usually acquired by inhalation of dust containing yeast cells which typically affects the lungs. Cryptococcosis symptoms include fever, malaise, cough, hemoptysis (bloody or blood-tinged sputum), headache, vision changes (blurry or double vision, photophobia) etc. Cryptococcosis diagnosis is clinical and microscopic, which is confirmed by culture or fixed-tissue staining.
According to the United Nations Program on HIV/AIDS and the World Health Organization, globally approximately one million cases of cryptococcosis are reported each year resulting in 625,000 deaths approximately. According to the Centers for Disease Control and Prevention and WHO, it is estimated that globally every year 220,000 cases of cryptococcal meningitis occur among people with HIV/AIDS, resulting in nearly 181,000 deaths. Therefore with the growing prevalence of cryptococcosis and availability of advance treatment are the key factors that drives the growth of cryptococcosis diseases market. However, adverse effects associated with the use of medication is likely to restrain the market growth in the forecast period.
